Table 1 PARP inhibitors under clinical investigation in malignant disease
From: Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?
Agent (year entered clinical research) | Manufacturer | Single/combination therapy | Oral/intravenous | Clinical indication(s) | Status |
|---|---|---|---|---|---|
AG014699, PF0367338 (2003) | Pfizer (New York, NY, USA) | Single agent; multiple combinations | Intravenous and oral | Solid tumours; melanoma; BRCA germline | Phase I and II melanoma studies complete. Phase II BRCA studies open |
KU59436, AZD2281, olaparib (2005) | AstraZeneca/KuDOS (London, UK) | Single agent; multiple combinations | Oral | Various, including BRCA germline | Phase I complete. Numerous phase II studies ongoing |
ABT-888, veliparib (2006) | Abbott Laboratories (North Chicago, IL, USA) | Multiple combinations | Oral | Solid tumours; melanoma; lymphoid malignancies | Phase 0/I completed in some indications Numerous phase II studies ongoing |
BSI-201, SAR 240550 iniparib (2006) | BiPar (South San Francisco, CA, USA; Sanofi Aventis) | Combination with gemcitabine and carboplatin; temozolomide | Intravenous | TNBC; lung cancer; glioma | Phase II studies completed. Phase III study in TNBC recruiting. Phase II study in lung near completion |
INO-1001 (2005/2006) | Inotek/Genentech (Lexington, MA, USA) | Single agent; combination with temozolomide | Intravenous | Melanoma; malignant glioma | Phase Ib in melanoma completed |
MK4827 (2008) | Merck Sharp Dohme (Hoddesdon, UK) | Single agent; combination with chemotherapy | Oral | Solid tumours; BRCA- related ovarian cancer | Phase I ongoing |
CEP-9722 (2009) | Cephalon (Frazer, PA, USA) | Single agent; combination with temozolomide | Oral | Solid tumours | Phase I ongoing |
GPI 21016 (2010) | MGI Pharma (Bloomington, MN, USA) | Combination with temozolomide | Oral | Solid tumours | Phase I ongoing |
E7016 (2010) | MGI Pharma (Bloomington, MN, USA), Eisai (Baltimore, MD, USA) | Combination with temozolomide | Oral | Solid tumours | Phase I ongoing |
LT673 (2011) | Lead Therapeutics/Biomarin (Novato, CA, USA) | Single agent and combination planned | Oral | Solid tumours | Phase I planned |